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Abstract
The contribution of renal and non‐renal clearance toward targeted concentrations and/or effects of therapeutic proteins in nephrotic patients are
unknown. This study dissected the contribution of clearance pathways to adalimumab elimination in patients with focal segmental glomerulosclerosis
(FSGS). Urine was collected from seven patients treated with adalimumab. Renal clearance (ClR) was measured and non‐renal clearance (ClNR) was
calculated as the difference between total clearance and ClR. Differences in cumulative amount in urine, ClR, and ClNR between study weeks 1 and 16 and
relationships between proteinuria (protein:creatinine ratio (Up/c)), and ClR and ClNR were evaluated. Up to 13% of the adalimumab dose was lost in
urine. ClNR contributedmore than ClR to enhanced total clearance. There was a nonlinear relationship betweenUp/c and ClR (R
2 0.7059); an increase in
ClR beginning at Up/c of 12 mg/mg [slope 1.755, (C.I.7.825 to 11.34)]. There was a linear relationship between Up/c and ClNR (R2 0.5039); for every
one unit increase in Up/c, ClNR would increase by 3.5 mL/hr (P ¼ 0.01). Both ClR and ClNR contribute to enhanced total clearance of adalimumab in
glomerular disease secondary to FSGS. Additional research is needed to identify mechanisms for the increased ClNR pathways.
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The use of therapeutic proteins for the treatment of
primary glomerular diseases has been increasing. Based
on results of the RAVE study, rituximab, an antibody
against CD20 on B cells, was FDA approved for the
treatment of kidney manifestations of anti‐neutrophil
cytoplasmic antibody (ANCA) associated small vessel
vasculitis in 2011.1 Several additional studies have
reported on the use of rituximab in patients with other
glomerular diseases including lupus nephritis, membra-
nous nephropathy, and focal segmental glomeruloscle-
rosis (FSGS).2–7 Adalimumab, a human monoclonal
antibody to TNF‐a, is effective in treating inﬂammatory
diseases including rheumatoid arthritis, ankylosing spon-
dylitis, Crohn’s, and psoriasis.8,9 Several publications
have reported the use of inﬂiximab, a therapeutic antibody
protein to TNF‐a, for the treatment of lupus nephritis.10,11
A major limitation to prescribing therapeutic proteins
in patients with glomerular disease is the lack of
knowledge of how the presence and/or severity of the
nephrotic syndrome inﬂuences the clearance of large
(molecular weight 145 kD) IgG‐based proteins. This is
particularly important given the expense of these agents
relative to small molecule therapeutics and the knowledge
that IgG, while not considered to be renally eliminated,
can be eliminated through the kidneys of proteinuric
patients.12 Additionally, hypercatabolism of IgG has been
reported in animal models of lupus and rheumatoid
arthritis.13,14
FSGS is one of the most common causes of primary
glomerular disease. It progresses to end stage kidney
disease in the majority of patients who have persistent
proteinuria despite treatment with steroids and other
immunosuppressive medications. Patients with FSGS
have elevated circulating levels of tumor necrosis
factor‐a (TNF‐a).15 An animal study reported upregula-
tion of kidney TNF‐a expression prior to the appearance
of proteinuria in Buff/Mna rats that spontaneously
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Pharmacokinetics
developed FSGS.16 We previously reported a Phase I
study that demonstrated safety and tolerability of
adalimumab in pediatric and young adult patients with
resistant FSGS.17 We evaluated the pharmacokinetics
(PK) of adalimumab in serum and found adalimumab
clearance values during single‐dose and multi‐dose
studies that were two‐ to ﬁvefold higher, respectively,
than previously reported values in patients with rheuma-
toid arthritis.17 This ﬁnding led to the current
investigation.
The current study evaluated the contribution of renal
versus non‐renal clearance to the increased total clearance
of adalimumab in patients with FSGS. Other objectives
were to evaluate the difference in renal and non‐renal
clearance values for adalimumab after a single‐ and
multiple‐ dose, and to evaluate the relationship between
urinary protein:creatinine excretion (Up/c) versus renal
and non‐renal clearance of adalimumab.
Methods
Ten patients with a diagnosis of FSGS were treated with
adalimumab as part of a phase I study.17,18 This study
received Institutional Review Board approval and was
conducted in accordance with the Declaration of Helsinki.
Patients received adalimumab 24 mg/m2 (maximum dose:
40 mg) subcutaneously every 14 days for 16 weeks. PK
variables were assessed after the ﬁrst dose of adalimumab
at week 0 and repeated at steady state, following the
week 16 dose, as previously reported.17 Urine was
collected at the following time intervals: 0–2, 2–12,
12–24, 24–36, and 36–42 hours—during the two PK
studies.
Urine samples from seven of the ten patients were
available for measurement of adalimumab concentrations
by an immunoassay (Q‐ADA, Sanquin Blood Supply’s
Monoclonal Therapeutics Laboratory, Netherlands).
Pharmacokinetics
Adalimumab serum PK variables, including total clear-
ance and area under the plasma concentration time curve
(AUC), were available from our previous analyses.17 The
cumulative amount of adalimumab in the urine was
calculated by multiplying the concentration by collection
volumes for each respective urine collection interval and
then summing the values over all of the intervals for each
subject during the PK assessment. Adalimumab renal
clearance was calculated as the cumulative amount
excreted in the urine over the 42 hours collection period
divided by the AUC. Since total clearance is the sum of
renal clearance and non‐renal clearance, adalimumab non‐
renal clearance was calculated as the total clearance minus
the renal clearance.
Statistics
The difference in cumulative amount of adalimumab
excreted in the urine and the difference in renal clearance
values and non‐renal clearance values at week 0 and week
16, respectively, were compared using a paired t‐test. The
relationships between Up/c in the ﬁrst morning specimen
versus renal and non‐renal clearance values of adalimu-
mab, respectively, were evaluated by regression.
Results
The demographics of the seven FSGS patients, for whom
urine samples were available, demonstrated an age of
18  10 years, Up/c of 12.1  5.6 mg/mg at baseline
(week 0) and 7.9  7.7 mg/mg at week 16, estimated
glomerular ﬁltration rate (eGFR) of 110  55 mL/min at
baseline (week 0) and 111  45 mL/min at week 16
(Table 1). Thus, at the start of the study all of the patients
had normal kidney function and nephrotic‐range protein-
uria. All but two patients had a reduction in the Up/c at
week 16. Additional data on the FSGS patients enrolled in
the Phase 1 adalimumab study were previously reported.17
Urines from the week 0 (single dose) collections were
available for analysis of adalimumab concentrations for
six out of seven patients. All seven patients had residual
urine samples for assessment of adalimumab concen-
trations at week 16. The cumulative amount of adalimu-
mab in the urine ranged from <1% of the dose to up to
Table 1. Patient Demographics
Patient ID Race
Age
(years)
Urine protein to
creatinine excretion at
week 0 (mg/mg)
Urine protein to
creatinine excretion at
week 16 (mg/mg)
Glomerular filtration
rate at week 0
(mL/min)
Glomerular filtration
rate at week 16
(mL/min)
1 White 13 9.2 14.0 174 152
2 Hispanic 15 20.0 22.0 204 152
3 White 27 11.1 6.7 71 74
4 White 6 15.0 6.9 89 79
5 White 20 9.1 4.4 88 66
6 Multi 9 17.0 0.6 62 173
7 White 36 3.6 0.6 85 84
Mean  St Dev 18  10 12.1  5.6 7.9  7.7 110  55 111  45
920 The Journal of Clinical Pharmacology / Vol 53 No 9 (2013)
13% of the dose. (Table 2)When comparing the amount of
adalimumab in the urine from week 0 to week 16, two
patients had an increase, while the remaining four had
consistent amounts (P ¼ 0.30). While the renal contribu-
tion to total clearance was substantially less than the non‐
renal contribution, it was >1% in 5 of the 13 (38%) doses
evaluated, with the highest value reaching 13%. Renal
clearance of adalimumab in patients without kidney
disease is expected to be zero.
The renal clearance of adalimumab at week 0 and
week 16 demonstrated an increase in three patients and a
stable amount in the other three patients (P ¼ 0.15)
(Figure 1a) The mean  standard deviation renal clear-
ance was 0.7  1.0 mL/hr and 1.6  2.5 mL/hr, at
week 0 and 16, respectively. The difference in non‐renal
clearance of adalimumab at week 0 and week 16
demonstrated an increase in one patient, a reduction in
two patients, and no change in three patients (P ¼ 0.70)
(Figure 1b). The mean  standard deviation nonrenal
clearance was 34.5  15.5 mL/hr and 36.2  45.9 mL/
hr, at week 0 and 16, respectively.
The relationships between proteinuria and renal
clearance of adalimumab demonstrated a direct relation-
ship by nonlinear regression analysis (slope 1.755 (C.I.
7.825 to 11.34), EC50 25.46 (C.I. 113.0 to 163.9), R2
0.7059). An increase in ClR was demonstrated beginning
at a Up/c of 12 mg/mg. (Figure 2a) The relationships
between Up/c versus non‐renal clearance of adalimumab
demonstrated a direct linear relationship (slope 3.5  1.1,
intercept 1.6  13.1, P ¼ 0.01) (Figure 2b).
Discussion
The current study was conducted in order to understand
the contributions of both renal and non‐renal elimination
routes toward the observation of increased total clearance
of adalimumab, an antibody against TNFa, in patients
with glomerular disease due to FSGS.17 We demonstrated
total clearance values for adalimumab that were 2‐fold
higher after a single dose and up to 5‐fold higher after
multiple doses as compared to published data from
patients with rheumatoid arthritis.17,19 The half‐life for
adalimumab was negatively related to the Up/c, suggest-
ing that as the amount of proteinuria increased the half‐life
became shorter.17 In light of our unexpected previous
ﬁndings and the lack of published reports evaluating the
urinary excretion of therapeutic antibodies in patients with
glomerular disease and heavy proteinuria, we assayed
urine adalimumab concentrations to determine (1) the
contribution of renal clearance to the enhanced total
clearance in patients with FSGS and (2) the relationship
between renal clearance and proteinuria.
Immunoglobulins are lost in the urine of nephrotic
patients, but are normally not eliminated in healthy
kidneys because of their large molecular weight.12 Loss of
therapeutic immunoglobulin proteins through the kidneys
Table 2. Renal and Nonrenal Clearance of Adalimumab in Nephrotic Syndrome
Patient ID AUC (mcg h/L)
Cumulative
amt. in urine at
42 hours
(mcg) CLtotal (mL/hr) CLR (mL/hr) CLNR (mL/hr)
Dose lost in
urine % CLR% CLNR%
Single dose
1 960,744 736 33.3 0.8 32.5 2.3 2.3 97.7
2 675,555 1,752 59.2 2.6 56.6 4.4 4.4 95.6
3 933,337 201 42.9 0.2 42.6 <1 0.5 99.5
4 1271,695 156 15.7 0.1 15.6 <1 0.8 99.2
5 2106,615 172 19.0 0.1 18.9 <1 0.4 99.6
6 610,551 105 41.0 0.2 40.8 <1 0.4 99.6
Mean 1093,083 520 35.2 0.7 34.5 1.8 1.5 98.5
St. Dev. 549,427 647 16.2 1.0 15.5 1.4 1.6 1.6
Multi‐dose
1 1039,801 4,083 30.8 3.9 26.9 12.8 12.8 87.2
2 282,069 1,794 141.8 6.4 135.5 4.5 4.5 95.5
3a 828,951 860 48.3 1.0 47.2 2.1 2.2 97.8
4 1466,865 59 13.6 0.0 13.6 <1 0.1 99.9
5 5000,434 145 8.0 0.0 8.0 <1 0.4 99.6
6 1881,984 0 13.3 0.0 13.3 <1 0 100
7 4368,529 45 9.2 0.0 9.2 <1 0.1 99.9
Mean 2124,090 998 37.8 1.6 36.2 3.3 2.9 97.1
St. Dev. 1827,910 1,510 48.1 2.5 45.9 4.4 4.7 4.7
ClR, renal clearance; ClNR, non‐renal clearance; Cltotal, total clearance.
aFor patient 007–002 data is from week 12. Values <1 were truncated to 1 for analysis of mean and standard deviation (SD).
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in patients with glomerular disease could have con-
sequences in terms of shorter drug half‐lives, enhanced
total clearance, and need for higher doses to achieve a
therapeutic response. The current data showed <1% to
13% of adalimumab was eliminated through the kidneys,
suggesting the need for up to a 13% increase in dose to
maintain targeted serum concentrations. The nonlinear
regression analysis demonstrated an increase in ClR
beginning at a Up/c of 12 mg/mg.
The neonatal Fc receptor is responsible for the
recycling and clearance of IgG and contributes to the
renal and non‐renal clearance of therapeutic antibodies.20
The neonatal Fc receptor is present in liver, intestine,
endothelial cells, placenta, skin, muscle, adipose, and
kidney,21,22 and it has been documented to be upregulated
in certain disease states.13,23 In the kidney, the neonatal Fc
receptor is found on glomerular epithelial cells and on the
apical membrane of proximal tubule epithelial cells.22
Functionally, it has been shown that the neonatal Fc
receptor on kidney podocytes is used to clear IgG that can
form immune complexes from the glomerular basement
membrane.24 Decreased functionality of the receptor at the
level of the podocyte could result in impaired IgG
clearance from glomeruli and enhanced damage as
reﬂected in proteinuria.24 Alternatively, altered expression
of the neonatal Fc receptor in the proximal tubule may
prevent tubular reabsorption of the ﬁltered load of IgG and
albumin. The relatively larger contribution of increased
non‐renal versus renal clearance to the increased
adalimumab total clearance was demonstrated in this
group of patients with FSGS. The linear regression
analysis suggested that for every 1 unit increase in urinary
protein excretion, the non‐renal clearance would increase
by 3.5 mL/hr. This clearance represents an 18‐ fold
greater contribution of non‐renal versus renal clearance
toward the increased total clearance. For a patient with a
Up/c of 10, the non‐renal clearance would be enhanced by
35 mL/min, roughly a third of the value for the total GFR.
Various mechanisms are possible for the demonstrated
increase in non‐renal clearance. Increased catabolism of
IgG based therapeutic antibodies through the neonatal Fc
receptor pathway is one mechanism based on studies in
patients with autoimmune diseases.13,14 However, it is not
known how or if the functionality of the liver (metabolic)
Figure 1. Adalimumab renal clearance (a) and non‐renal clearance (b) at
weeks 0 and 16 for the six matched patients. The clearance of
adalimumab at week 0 and week 16 demonstrated a non‐significant
increase in renal (P ¼ 0.15) and non‐renal (P ¼ 0.70) values from study
initiation until completion within patients.
Figure 2. Regression of urine protein to creatinine ratio to adalimumab
renal clearance (ClR) (a) and non‐renal clearance (ClNR) (b). The
relationships between urinary protein:creatinine (Up/c) excretion versus
ClR of adalimumab demonstrated a positive direction by nonlinear
regression analysis (slope 1.755 (C.I.7.825 to 11.34), ED50 25.46 (C.I.
113.0 to 163.9), R2 0.7059). Nonlinear regression demonstrated an
increase in ClR beginning at a Up/c of 12 mg/mg (a). A positive
relationship by linear regression analysis (slope 3.5  1.1, intercept
1.6  13.1, P ¼ 0.01) was demonstrated for urine protein to
creatinine ratio versus adalimumab ClNR (b). Both graphs demonstrate
the 95% confidence intervals.
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neonatal Fc receptor tracks with the kidney podocyte
receptor. Enhanced function of the liver neonatal Fc
receptor could contribute to increased non‐renal clearance
of adalimumab.
Production of antibodies to adalimumab is another
plausible mechanism for increased clearance, although
these were not assessed in this patient group. A recent
study in patients with rheumatoid arthritis receiving
adalimumab reported that 15% of patients had anti‐
adalimumab antibodies after 16 weeks of therapy.25
However, the FSGS patients receiving adalimumab had
total clearance values that were twofold higher than in
rheumatoid arthritis patients at the time of the ﬁrst dose,
suggesting that anti‐adalimumab antibodies were not
responsible for this increase in non‐renal clearance. A
combined contribution of enhanced renal clearance,
increased catabolism of adalimumab through the neonatal
Fc receptor (enhanced non‐renal clearance), and produc-
tion of anti‐adalimumab antibodies may account for the
increased total clearance in FSGS patients.
While the results of the current study are novel and
interesting, several study limitations are noted. Our current
assessments only evaluated adalimumab as a therapeutic
antibody. It is currently unknown whether the consistent
ﬁndings would be observed with other therapeutic
antibodies or other proteins. The current study also only
included seven patients, necessitating a larger study to
conﬁrm the novel ﬁndings. Only nephrotic patients with
FSGS receiving adalimumab were evaluated in the current
study. The applicability of these results to patients with
lower levels of proteinuria is not known. Future
experimental plans include assessing additional biologic
proteins and evaluating the mechanisms underlying the
ﬁnding of enhanced nonrenal clearance.
Conclusions
Enhanced renal and non‐renal clearance pathways
contribute to the increased total clearance of adalimumab
in patients with glomerular disease secondary to FSGS.
Given the increased use of therapeutic proteins in patients
with glomerular disease and nephrotic‐range proteinuria,
additional study on PK and pharmacodynamics in these
patient populations is warranted. Since some therapeutic
proteins are used off‐label for the treatment of glomerular
disease, the clinician should be aware of the need for dose
adjustment in patients with signiﬁcant proteinuria who are
prescribed these biological agents. Further research is
needed to discern the mechanisms for enhanced non‐renal
clearance of adalimumab in glomerulopathies such as
FSGS. The results from the current research, which
evaluated adalimumab, could be used to inform about the
possibility of clearance alterations for other therapeutic
proteins used to treat patients with proteinuric forms of
kidney disease.
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